New drug combo shows promise in advanced breast cancer trial
Disease control
Completed
This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination helps control the cancer. Participants had cancer that had spread or returned, …
Phase: PHASE1 • Sponsor: Otto Metzger, MD • Aim: Disease control
Last updated May 12, 2026 13:40 UTC